FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Matrixyl

Palmitoyl Pentapeptide-4 / Pal-KTTKS

Beauty & Skincare

Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is a cosmetic peptide consisting of a palmitoyl group attached to the pentapeptide lysine-threonine-threonine-lysine-serine, designed to stimulate collagen and extracellular matrix production in dermal fibroblasts. It was developed by Sederma and is one of the most extensively studied and commercially successful topical anti-aging peptides. Matrixyl functions as a matrikine, mimicking the activity of collagen breakdown fragments to signal fibroblasts to produce new collagen, fibronectin, and glycosaminoglycans.

작용 메커니즘

Lipopeptide consisting of a palmitoyl group linked to the pentapeptide KTTKS (a collagen I fragment). Acts as a matrikine, signaling fibroblasts to increase collagen I, III, and IV synthesis, fibronectin production, and hyaluronic acid production via TGF-beta pathway activation.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Topical application at 2-8% concentration in serums. Applied twice daily. Synergistic with retinol and vitamin C. Results visible after 8-12 weeks of consistent use. Not injected.

연구 노트

Clinical Research Status

Matrixyl has been the subject of multiple clinical studies demonstrating measurable anti-wrinkle efficacy when applied topically at concentrations of 2-5% in appropriate formulations. Double-blind placebo-controlled trials have shown statistically significant improvements in wrinkle depth, skin roughness, and overall photoaging scores after 2-4 months of regular application. It is widely incorporated into commercial skincare products and is recognized by dermatologists as one of the more evidence-based cosmetic peptides available.

Key Published Findings

In vitro studies demonstrate that Matrixyl stimulates collagen I synthesis by up to 350% and collagen IV synthesis by up to 200% in human fibroblast cultures at relevant concentrations. Clinical measurements using profilometry show wrinkle depth reduction of up to 36% after 4 months of twice-daily application in controlled studies. The palmitic acid chain enhances skin penetration and cell membrane interaction compared to the naked KTTKS peptide, which showed limited bioavailability without the lipophilic modification.

Safety Profile

Matrixyl has an excellent safety profile with no reported systemic side effects, sensitization, or phototoxicity in clinical testing, consistent with its topical application and local mechanism of action. Skin irritation is extremely rare and typically associated with other formulation ingredients rather than the peptide itself. It is considered safe for use during pregnancy and lactation at cosmetic concentrations, though formal reproductive toxicology studies have not been conducted.

Comparison to Related Compounds

Matrixyl 3000 is a newer generation product combining Matrixyl (pal-KTTKS) with palmitoyl tripeptide-1 for enhanced synergistic collagen stimulation through complementary pathways. Compared to retinoids, Matrixyl provides collagen stimulation without the associated irritation, photosensitivity, or retinization period, though efficacy is generally considered more modest. Argireline (acetyl hexapeptide-3) works through an entirely different mechanism (neuromuscular modulation) and is complementary rather than competitive with Matrixyl in anti-aging formulations.

Community Observations

Skincare enthusiasts consider Matrixyl one of the best-supported peptides for anti-aging, often incorporated into daily serums alongside vitamin C, niacinamide, and hyaluronic acid. Results are typically reported as gradual improvements in skin texture and fine line appearance over 2-3 months of consistent use. The peptide is available in numerous commercial products ranging from drugstore to luxury price points, with concentration and formulation quality varying significantly across brands.

반감기

N/A (topical)

재조성

N/A (topical formulation)

보관

건조한 상태

Room temperature. Stable in cosmetic formulations.

재조성된 상태

Stable in formulation. Protect from excessive heat.

미국 법적 상태

Cosmetic ingredient (unregulated)

또는 알려진 이름으로

Palmitoyl Pentapeptide-4Pal-KTTKS

자주 묻는 질문

Matrixyl란 무엇인가요?

Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is a cosmetic peptide consisting of a palmitoyl group attached to the pentapeptide lysine-threonine-threonine-lysine-serine, designed to stimulate collagen and extracellular matrix production in dermal fibroblasts. It was developed by Sederma and is one of the most extensively studied and commercially successful topical anti-aging peptides. Matrixyl functions as a matrikine, mimicking the activity of collagen breakdown fragments to signal fibroblasts to produce new collagen, fibronectin, and glycosaminoglycans.

Matrixyl는 어떻게 작용하나요?

Lipopeptide consisting of a palmitoyl group linked to the pentapeptide KTTKS (a collagen I fragment). Acts as a matrikine, signaling fibroblasts to increase collagen I, III, and IV synthesis, fibronectin production, and hyaluronic acid production via TGF-beta pathway activation.

Matrixyl의 미국 규제 현황은 어떤가요?

Cosmetic ingredient (unregulated)

Matrixyl의 반감기는 얼마인가요?

N/A (topical)

Matrixyl의 다른 이름은 무엇인가요?

Palmitoyl Pentapeptide-4, Pal-KTTKS

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기